Article: Pyrotinib-associated acute kidney injury: A case report

Pyrotinib is a novel human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI). Previous studies of pyrotinib showed that it is mainly excreted through the gastrointestinal tract rather than the kidneys, with little effect on renal function. Here, we report a patient with HER2-mutated nonsmall cell lung cancer who developed acute kidney injury (AKI) after receiving pyrotinib treatment. This case alerts clinicians to the adverse renal effects of HER2 TKIs, especially in patients with chronic kidney disease. However, tumor treatment should remain a priority in clinical practice. In this case, AKI induced by pyrotinib was reversible. Therefore, there is no need to restrict the use of HER2 TKIs due to concerns about possible nephrotoxicity.

Citing Articles

Pyrotinib-associated acute kidney injury: A case report.

Miao K, Zhang L, Si X Cancer Innov. 2023; 1(4):344-347.

PMID: 38089087 PMC: 10686108. DOI: 10.1002/cai2.38.

References

1.

Mazieres J, Peters S, Lepage B, Cortot A, Barlesi F, Beau-Faller M . Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31(16):1997-2003. DOI: 10.1200/JCO.2012.45.6095. View

2.

Cosmai L, Gallieni M, Porta C . Renal toxicity of anticancer agents targeting HER2 and EGFR. J Nephrol. 2015; 28(6):647-57. DOI: 10.1007/s40620-015-0226-9. View

3.

Seethapathy H, Zhao S, Chute D, Zubiri L, Oppong Y, Strohbehn I . The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019; 14(12):1692-1700. PMC: 6895474. DOI: 10.2215/CJN.00990119. View

4.

Zhou C, Li X, Wang Q, Gao G, Zhang Y, Chen J . Pyrotinib in -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2020; 38(24):2753-2761. DOI: 10.1200/JCO.20.00297. View

5.

Ozkok A, Edelstein C . Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014; 2014:967826. PMC: 4140112. DOI: 10.1155/2014/967826. View

6.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

7.

Zhu Y, Li L, Zhang G, Wan H, Yang C, Diao X . Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1033-1034:117-127. DOI: 10.1016/j.jchromb.2016.08.009. View

8.

Oh D, Bang Y . HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2019; 17(1):33-48. DOI: 10.1038/s41571-019-0268-3. View

9.

Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G . Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Target Oncol. 2017; 12(5):563-569. DOI: 10.1007/s11523-017-0510-9. View

10.

Liu Y, Zhang Q, Lu C, Hu W . Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults. Drug Des Devel Ther. 2021; 15:2485-2493. PMC: 8203185. DOI: 10.2147/DDDT.S312310. View

11.

Miao K, Zhang L, Si X . Pyrotinib-associated acute kidney injury: A case report. Cancer Innov. 2023; 1(4):344-347. PMC: 10686108. DOI: 10.1002/cai2.38. View

Pyrotinib-associated Acute Kidney Injury: A Case Report